SBHMY Stock Sino Biopharmaceutical (SBHMY) is expected to pay dividends on October 08, 2025

GET DAILY SIGNALS

Get AI intraday signals

A dividend of $0.13 per share will be paid with a record date of October 08, 2025, and an ex-dividend date of August 29, 2025. The last dividend of $0.2 was paid on July 25, 2025. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.

SBHMY's Indicator enters downward trend

The Aroon Indicator for SBHMY entered a downward trend on November 19, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 153 similar instances where the Aroon Indicator formed such a pattern. In of the 153 cases the stock moved lower. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SBHMY as a result. In of 43 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SBHMY turned negative on November 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at .

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.452) is normal, around the industry mean (27.312). P/E Ratio (29.781) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (2.629) is also within normal values, averaging (1.886). Dividend Yield (0.013) settles around the average of (0.049) among similar stocks. P/S Ratio (3.815) is also within normal values, averaging (321.020).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SBHMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBHMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.